Adverse Effects of Oxytocin Are More Prevalent than Those Associated with Carbetocin Administration During Cesarean Section
Journal of Clinical Medicine · 13.10.2025 · 14 (20) · 7211
DOI: 10.3390/jcm14207211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.10.2025. Verfasst von Edyta Zagrodnik und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Department of Anesthesiology and Intensive Care of Adults and Children, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The aim of this study is to analyze the frequency and type of subjective adverse events reported after the use of oxytocin and carbetocin in women giving birth by cesarean section.
Methods
A total of 70 pregnant women, previously scheduled for elective cesarean section, were enrolled in this study and divided into two groups. One group (OXY) received intrapartum oxytocin at a dose of 5 IU intravenously, and the other group (CARBE) received intrapartum carbetocin at a dose of 100 μg intravenously. Both drugs were used alternately to contract the uterus immediately after the expulsion of baby during the cesarean section.
Results
An analysis of reported subjective adverse symptoms associated with the administration of uterotonic drugs showed a higher incidence of adverse effects in the group of women receiving oxytocin compared to those receiving carbetocin. Statistical significance was observed for all of the following reported symptoms: headache, chest pain, burning sensation and heaviness in the chest, and palpitations.
Conclusions
Although chest pain, burning and heaviness in the chest, palpitations, and headaches are more common in women giving birth by cesarean section after administration of oxytocin than after administration of carbetocin, this fact appears to be of limited clinical significance from a clinical point of view.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Department of Anesthesiology and Intensive Care of Adults and Children, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland.
- Department of Bromatology and Nutritional Diagnostics, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland.
- Department of Neonatology, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland.
- Department of Plastic, Endocrine and General Surgery, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland.
- Department of Gynecology, Endocrinology and Gynecological Oncology, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland.
- Department of Anaesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland.
ORCID-Profile: Edyta Zagrodnik, Małgorzata Szczuko, Anna Surówka, Iwona Szydłowska, Maciej Ziętek
Zitieren
APA
Zagrodnik, E., Szczuko, M., Kordek, A., Surówka, A., Szydłowska, I., Rzewuska, B., Steblovnik, L., & Ziętek, M. (2025). Adverse Effects of Oxytocin Are More Prevalent than Those Associated with Carbetocin Administration During Cesarean Section. Journal of Clinical Medicine, 14(20), 7211. https://doi.org/10.3390/jcm14207211
Vancouver
Zagrodnik E, Szczuko M, Kordek A, Surówka A, Szydłowska I, Rzewuska B, et al. Adverse Effects of Oxytocin Are More Prevalent than Those Associated with Carbetocin Administration During Cesarean Section. Journal of Clinical Medicine. 2025;14(20):7211. doi:10.3390/jcm14207211
BibTeX
@article{Zagrodnik2025,
author = {Zagrodnik, Edyta and Szczuko, Małgorzata and Kordek, Agnieszka and Surówka, Anna and Szydłowska, Iwona and Rzewuska, Beata and Steblovnik, Lili and Ziętek, Maciej},
title = {Adverse Effects of Oxytocin Are More Prevalent than Those Associated with Carbetocin Administration During Cesarean Section},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {20},
pages = {7211},
doi = {10.3390/jcm14207211}
}
EUVIMED